Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03171025 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
A Phase 2 study of Bladder Cancer, sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT03171025 is a Phase 2 study of Bladder Cancer that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 200 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03171025, a Phase 2 study of Bladder Cancer, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03171025
The ClinicalTrials.gov registry entry for NCT03171025 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03171025 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Utah.
Frequently Asked Questions
What is clinical trial NCT03171025 about?
NCT03171025 is a clinical study titled "Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer". This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.
What is the current status of trial NCT03171025?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2017-07-10. Estimated completion is 2027-10-31.
What conditions does trial NCT03171025 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT03171025?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03171025?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03171025 being conducted?
This trial has 2 study locations across Florida, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.